PARADEEP PHOSPHATES LTD · QQ1 FY-2027 · THE CALL

Strong volume growth masked by raw-material headwinds and margin normalization

The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.

Q1 FY27 results PARADEEPParadeep Phosphates Ltd19 Aug 2026 · 6 min read

Verdict

Hold

confidence 7/10

Credibility

Grade B

Met prior guidance: backward-integration benefits realized (sulph acid +32%, phos acid +7%). Phosphoric acid Phase-I on track (1 lakh tons by Dec). New quantitative guidance ₹5,000/MT normalized EBITDA; credible if raw material stabilizes and government support continues.

Short-term outlook

Cautiously Optimistic

next 1–2 quarters

Long-term outlook

Optimistic

multi-year

Company delivered 63% revenue growth with backward-integration benefits (sulph acid +32%, phos acid +7%) and market-share gains (13% volume growth vs 1% industry). EBITDA per ton ₹7,000 is strong but inventory-aided; normalized ₹5,000/MT guidance signals -29% margin compression if raw-material costs remain elevated. Near-term headwind: sulphur $1,000+/MT (up $150 in 3 months), 70–75% global trade via geopolitical risk zone, government DAP price caps limiting pass-through. Long-term strategy credible (₹3,500+ Cr capex, AlF3 diversification), but dependent on execution and macro stabilization. Key risk: subsidy receivable ₹4,600 Cr (75% of quarterly PAT) exposes cash flow to government timing.

₹6124.3 Cr

Revenue · +63.1% YoY

₹392.5 Cr

Reported PAT · +53.4% YoY

Expanding

Margins · vs guidance: Mixed

Did the claims hold up?

Management's claims vs. the numbers

Revenue increased 36% YoY to ₹6,124 Cr

MISS

Delivered result shows 63.1% YoY revenue growth to ₹6,124 Cr

Sulphuric acid production 32% higher YoY

MET

Delivered backward integration benefits; sulphuric acid capacity fully utilized

Phosphoric acid production 7% higher YoY

MET

Consistent with phase-I expansion narrative and capacity buildup

EBITDA per ton ₹7,000; normalized ₹5,000 after cost stabilization

MET

EBITDA ₹742 Cr / 9.85 L tons = ₹7,530/MT (vs prior ₹6,500). Inventory benefit acknowledged.

Traded volumes to offset production gaps; overall market share maintained

MET

Pragmatic hedging; 500k tons imports secured for rabi. DAP volume +55%, NPK -9% but farmer sales +6%.

Earnings quality

What changed since the last call

Deltas vs. the prior call

Backward integration materializing ahead of guidance

Upgrade

Sulph acid +32% YoY, phos acid +7% YoY; capacity fully utilized. Prior guidance: 'benefits expected in FY27' → realized.

Product mix tactical shift to DAP

Neutral

DAP volume +55% (₹1,350/bag govt cap), NPK –9% volume but +6% farmer sales. Optimization for profitability amid subsidy caps; long-term NPK focus unchanged.

Non-subsidy diversification approved

Upgrade

₹250 Cr AlF3 plant capex approved (15,000 MTPA, ₹50+ Cr EBITDA). Long-term target 20% EBITDA from non-subsidy. New strategic pillar beyond fertilizer.

Normalized EBITDA guidance formalized

Neutral

Prior: vague 'benefits from backward integration' → Current: ₹5,000/MT normalized (vs ₹7,000 Q1 aided by inventory). New quantitative anchor; dependent on cost stabilization.

Capacity ramp timelines reaffirmed

Maintained

Phos acid Phase-I (5→7L tons) on track: 1L by Dec, 1L by Aug FY28. Contracts awarded, equipment ordered. No delays vs prior guidance.

The Q&A

Analysts pressed on raw-material sourcing strategy, sustainability of ₹5,000/MT normalized margin, and AlF3 demand validation. Management transparent on sulphur volatility (spot basis, no hedges) but withheld cost basis (commercially sensitive). Held firm on expansion timelines and long-term strategy despite acknowledging unprecedented geopolitical disruption.

The exchanges that mattered

Raw material sourcing Q2 — Prashant Biyani, Elara Securities

Partial

Evaluating options. Targeting ~70% phos acid capacity utilization; backward integration still strategic. Augmenting via imported DAP/NPK for rabi.

AlF3 plant capex & returns — Prashant Biyani, Elara Securities

Answered

22–24 months (Mar 2028 target). ₹180–200 Cr annual revenue, ₹50+ Cr EBITDA. 15,000 MTPA capacity. B2B sales to aluminum smelters in Odisha.

Product mix: DAP +55%, NPK –9% — Aman Kothari, Aequitas Investments

Answered

DAP more profitable due to govt subsidy structure. Tactical Q1 shift; long-term strategy remains NPK-focused. Farmer NPK sales +6% (price-driven volume decline offset). Price normalization could reverse shift.

EBITDA sustainability — Saumil Shah, Paras Investments

Answered

₹7,000 Q1 aided by low-cost inventory. Realistic normalized EBITDA ₹5,000/MT per year. Once expansions complete (2–2.5 yrs), should reach ₹7,000+ sustained.

Market share gains vs flat industry — Dev Gulwani, Care PMS

Answered

Balanced regional presence (N, E, W, S), strong brands (Jai Kisaan Navratna, Mangala), backward integration (OCP rock secured), product mix flexibility. Grew farmer sales 15–16% vs 1% industry.

Sulphur pricing trends — Vignesh Iyer, Sequent Investments

Partial

Q1 average $850/MT, now $1,000+/MT. No long-term contracts (volatility prevents). Currently spot-basis only. Commercially sensitive to disclose exact cost.

Expansion timeline tracking — Dhruv Muchhal, HDFC AMC

Answered

Phos acid Phase-I: 5→6L tons by Dec, 6→7L tons by Aug FY28 (on track). Equipment ordered, contracts awarded. Big expansion (3L tons) starting Q2 FY29 (no delay).

Capex and normalized EBITDA guidance — Manish Mahawar, Antique Stock Broking

Partial

Big capex FY29–30 starting Q2 FY29 (phased). Sustainable ₹5,000/MT target; depends on cost normalization and government coordination on subsidy support.

Subsidy receivable and collections — Archit Agarwal, Steptrade Capital

Answered

Outstanding subsidy ₹4,600 Cr as of 30 Jun. Q1 received ₹2,650 Cr (22% higher YoY). Operating cash flow positive; inventory liquidated.

NPK adoption drivers beyond pricing — Aman Kothari, Aequitas Investments

Answered

Farmer awareness on soil health and balanced fertilization. Sulphur deficiency in soil makes NPK valuable. Market 24M tons phosphate (10M DAP, 14M NPK). If govt removes DAP MRP cap, portfolio rebalances.

Guidance

Forward guidance and management's confidence

No explicit FY27 revenue target. Volume growth expected offset by DAP mix shift and trading.

Low

Q1 ₹6,124 Cr; company deferring full-year guidance due to macro volatility. Signaling volume discipline over revenue headline.

EBITDA per MT: ₹5,000 normalized; ₹7,000+ once expansions complete (2–2.5 yrs).

Medium

Q1 ₹7,000 aided by inventory. Normalized ₹5,000 assumes raw-material stabilization + government subsidy support. Dependent on external factors.

FY27: Phos acid Phase-I (5→6L by Dec, 6→7L by Aug FY28). Granulation debottleneck 3.7→4L by Dec. AlF3 plant start (₹250 Cr total).

High

Contracts awarded, equipment ordered. Execution tracking on schedule. No delays signaled.

FY29–30: Big expansion 3L tons phos+sulph acid (₹3,500–3,600 Cr). Start Q2 FY29 (mid-fiscal).

Medium

Multi-year project. Final commercial discussions ongoing. Timing and cost subject to macro conditions (raw-material prices, financing).

Risks the call surfaced

Ranked by how much they should concern a holder

Raw material volatility

High

Sulphur prices +18% Q1 avg ($850/MT), now $1,000+/MT. 70–75% global sulphur/ammonia trade via Strait of Hormuz (geopolitical risk). Company on spot basis only, no hedges.

Subsidy receivable concentration

High

₹4,600 Cr outstanding subsidy (75% of Q1 PAT ₹392.5 Cr). Government payment delays would severely impact working capital and liquidity. Collections volatile by policy.

Government price caps

High

DAP MRP capped at ₹1,350/bag by govt. NPK prices ₹2,100–2,500/bag (uncapped). Cap prevents passing raw-material cost inflation to farmers; margins compressed.

Capacity project execution

Medium

₹3,500–3,600 Cr big-expansion capex (3L tons phos+sulph acid) over FY29–30. Timing critical for achieving ₹7,000+ EBITDA/MT. Delays would defer earnings uplift.

Normalized EBITDA miss risk

Medium

₹5,000/MT normalized EBITDA guidance depends on raw-material stabilization + government support. Q1 ₹7,000 via inventory benefit; normalization is -29% drag. Risk: if costs stay elevated or gov support withheld, EBITDA undershoots.

Management

Score 7/10. Transparent on raw-material volatility and hedging strategies (tactical DAP shift, 500k tons imports secured, trading volumes). Some commercial sensitivity (sulphur cost basis, AlF3 supplier details withheld). Clear on expansion timelines, phased ramps, and inventory-benefit disclaimer. Answers detailed but occasionally qualify on government support dependency. Strong on backward integration (sulph acid +32%, phos acid +7% delivered as expected). Phase-I phosphoric-acid expansion timelines being met (contracts awarded, equipment ordered). Debt reduction (₹700 Cr paydown) despite macro headwinds shows operational discipline. Met prior FY26 guidance on backward-integration benefits.

What to watch next

1 · Dec 2026 (Q3 FY27)
Phosphoric acid Phase-I: 5→6 lakh tons ramp. Granulation debottleneck 3.7→4 lakh tons target.
2 · Aug 2027 (Q1 FY28)
Phosphoric acid Phase-I final: 6→7 lakh tons capacity online. Capacity utilization expansion.
3 · Q2 FY29 (Sep 2028)
Big expansion capex ramp start: ₹3,500–3,600 Cr, 3 lakh tons phos+sulph acid capacity. Multi-quarter build.

Key risk: subsidy receivable ₹4,600 Cr (75% of quarterly PAT) exposes cash flow to government timing.

Informational and educational content only. Not investment advice.